Neo-NTP-CRT for Locally Advanced ESCC
The investigators hypothesize that nivolumab combined with neoadjuvant chemoradiotherapy (CRT) is safe and effective in patients with locally advanced esophageal squamous cell carcinoma (LAESCC).
Locally Advanced Esophageal Squamous Cell Carcinoma
DRUG: Nivolumab
change in treatment related death, no increase of treatment-related death within 30 days after esophagectomy, 30 days|rate of completion of protocol treatment, successful completion of preoperative therapy and processing to surgery without any extended treatment-related delay, which is defined as \> 19 weeks after the first dose of nivolumab (d-14) in neo-NTP-CRT (19 weeks include 15 weeks of protocol treatment plus 4 weeks of flexibility.)., 5 months
The investigators hypothesize that nivolumab combined with neoadjuvant chemoradiotherapy (CRT) is safe and effective in patients with locally advanced esophageal squamous cell carcinoma (LAESCC).